Skip to main content

and
  1. No Access

    Article

    A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer

    Irinotecan/cisplatin (IP) is an active regimen for extensive-disease small-cell lung cancer (ED-SCLC). However, the optimal dose/schedule is unsettled. To evaluate the efficacy and safety of a dose-intensified...

    Ji-Youn Han, Dae Ho Lee, Sung Young Lee, Chun Gun Park, Hae Young Kim in Medical Oncology (2005)